Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...181182183184185186187188189190191...10651066»
  • ||||||||||  dexamethasone / Generic mfg., progesterone / Generic mfg.
    Journal:  Crystal Structure and Biochemical Analysis of a Cytochrome P450 Steroid Hydroxylase (BaCYP106A6) from Bacillus Species. (Pubmed Central) -  Mar 29, 2023   
    This structural characterization and comparison with other bacterial steroid hydroxylase CYPs allowed us to identify a unique Arg295 residue that may serve as the key residue for substrate specificity and regioselectivity in BaCYP106A6. This observation provides valuable background for further protein engineering to design commercially useful CYP steroid hydroxylases with different substrate specificities.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Review, Journal:  Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma. (Pubmed Central) -  Mar 29, 2023   
    The triplet regimen uses less bortezomib and dexamethasone during the first 24 weeks of treatment. The efficacy and safety profiles of selinexor-bortezomib-dexamethasone, combined with its once-weekly administration of selinexor and bortezomib, make it a useful additional triplet therapy option for previously treated multiple myeloma.
  • ||||||||||  Empliciti (elotuzumab) / AbbVie, BMS
    Trial termination:  Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide (clinicaltrials.gov) -  Mar 29, 2023   
    P2,  N=18, Terminated, 
    Our results indicate the intermediate-term safety of repeated transforaminal epidural low-dose dexamethasone injections with regard to the effect on glucose profile and pituitary-adrenal axis functions. Completed --> Terminated; Sponsor no longer providing drug
  • ||||||||||  dexamethasone sodium phosphate (AVM0703) / AVM Biotechnology
    Trial completion date, Trial primary completion date, Immunomodulating:  The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies (clinicaltrials.gov) -  Mar 29, 2023   
    P1/2,  N=144, Recruiting, 
    Initiation date: Sep 2022 --> May 2023 | Trial primary completion date: Sep 2024 --> Dec 2024 Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Apr 2023 --> Apr 2025
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment open, Trial completion date, Trial primary completion date:  Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab (clinicaltrials.gov) -  Mar 29, 2023   
    P2,  N=30, Recruiting, 
    Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025 Unknown status --> Recruiting | Trial completion date: Dec 2019 --> Dec 2025 | Trial primary completion date: Dec 2019 --> Dec 2025
  • ||||||||||  dexamethasone prodrug (101-PGC-005) / 101 Therap
    Enrollment closed:  101-PGC-005 for the Treatment of COVID-19 (clinicaltrials.gov) -  Mar 29, 2023   
    P2/3,  N=329, Active, not recruiting, 
    Unknown status --> Recruiting | Trial completion date: Dec 2019 --> Dec 2025 | Trial primary completion date: Dec 2019 --> Dec 2025 Recruiting --> Active, not recruiting
  • ||||||||||  Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    COVID-19 VACCINATION AND COVID 19 INFECTION IN ATYPICAL HEMOLYTIC UREMIC SYNDROME: ONE SINGLE CENTER STUDY IN TAIWAN () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1629;    
    One case (already had 2 doses COVID 19 vaccination) needed hospitalization and improved after remdesivir and dexamethasone treatment who with mild aHUS disease activity progression...One case (complete three doses COVID 19 vaccination) refused Molnupiravir treatment and had mild aHUS disease activity progression...aHUS disease activity should be close monitor especially after COVID 19 vaccination, during COVID 19 infection and after COVID 19 infection. Remdesivir and Molmupiravir are relative safe to use for aHUS cases.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    RENAISSANCE OF EQUINE ANTITHYMOCYTE GLOBULIN IN RENAL TRANSPLANTATION () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1467;    
    Equine ATG (eATG) has been used less compared to rabbit ATG(rATG) in tranplantation...Group A- contained HLA matched first degree relatives as renal donors and induction agent was injection Methylprednisolone (MP)...Conclusions eATG can be used as induction and antirejecton therapy agent in TCMR in renal transplantation. eATG is economical compared to rATG.
  • ||||||||||  ISOLATED COLONIC HISTOPLASMOSIS IN RENAL TRANSPLANT RECIPIENT POST COVID-19 INFECTION () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1451;    
    He had history of fever and diarrhea in February 2022 and was diagnosed COVID-19 positive with RT-PCR, and was treated conservatively with intravenous dexamethasone and lowering of immunosuppressants...Results He was treated with intravenous liposomal amphotericin B for initial two weeks followed by oral itraconazole...Prolonged use of immunosuprresants, use of antirejection therapies (like high dose pulse methyl prednisolone and bortezomib) and even in some case reports COVID 19 infection have shown to increase the risk of histoplasmosis. Primary and isolated colonic histoplasmosis like in this case can be the atypical presentation which emphasizes the importance of maintaining a low threshold for consideration of histoplasmosis in renal allograft recipients.
  • ||||||||||  THE BITE OF WOLF IN THE TWILIGHT YEARS : LATE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1198;    
    She has underlying Hashimoto thyroiditis diagnosed 3 years ago and is stable on oral levothyroxine maintenance therapy...Results She was given immunosuppression induction therapy with oral prednisolone 60mg once daily and oral mycophenolate mofetil 1g twice daily...She is yet to achieve remission and her immunosuppression was continued till her next clinic review. Conclusions Occurrence of SLE with lupus nephritis is rare in elderly and may render significant morbidity or mortality if undiagnosed or untreated.
  • ||||||||||  budesonide / Generic mfg.
    A new therapeutic strategy in severe IgA nephropathy by MP pulse and SVF () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_897;    
    Introduction One of the most common chronic glomerulonephritis is IgA nephropathy but as yet there is no definitive specific therapeutic means especially when associated with chronic kidney disease, but giving RAAS blocker, omega-3, budesonide, endothelin-A blocker, monoclonal antibodies to inhibit complement system, however more than 50% of IgAN with CKD patients are fall into CKD stage 5 and need a renal replacement therapy...Follow up renal biopsy after 1 year showed basically same morphology without progression, however mesangial deposits are almost negative compare to heavy mesangial deposits at initial biopsy. Conclusions Although further studies by large numbers are mandatory, methylprednisolone pulse therapy followed by autologous SVF therapy might be a promising therapeutic means in severe IgA nephropathy with CKD.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    ACUTE KIDNEY INJURY IN SCLERODERMA - IT'S NOT ALWAYS RENAL CRISIS () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_760;    
    He was treated for SS with rituximab and cyclophosphamide in 2009...He was commenced on intravenous methylprednisolone and booked for a renal biopsy...It can also present with hypertension and AKI. Here we highlight the diagnostic uncertainty of AKI in the context of SS and the importance of investigating with biopsy for vasculitis in selected patients.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Avastin (bevacizumab) / Roche
    ECULIZUMAB FOR BEVACIZUMAB-INDUCED THROMBOTIC MICROANGIOPATHY () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_660;    
    Here we highlight the diagnostic uncertainty of AKI in the context of SS and the importance of investigating with biopsy for vasculitis in selected patients. Methods The clinical and laboratory data of 8-yrs old patient with
  • ||||||||||  Darzalex (daratumumab) / J&J
    Journal:  Putting the best foot forward when treating newly diagnosed multiple myeloma. (Pubmed Central) -  Mar 28, 2023   
    In Australia, patients receive sequential lines of novel agent (NA)-based lines of therapy (LOTs), including proteasome inhibitors, immunomodulatory drugs and CD38-targeting monoclonal antibodies within the constraints of the pharmaceutical benefits scheme. We propose that induction with a quadruplet incorporating all three drug classes and dexamethasone at diagnosis is the best approach to gain disease control.
  • ||||||||||  hydrocortisone / Generic mfg., triptorelin / Generic mfg.
    Journal:  Genetic analysis of a case with 11? hydroxylase deficiency caused by CYP11B2/CYP11B1 chimeric gene (Pubmed Central) -  Mar 28, 2023   
    We propose that induction with a quadruplet incorporating all three drug classes and dexamethasone at diagnosis is the best approach to gain disease control. 11?-OHD may be misdiagnosed as 21-OHD due to the potential CYP11B2/CYP11B1 chimeric gene, which will require multiple methods for the detection.
  • ||||||||||  budesonide / Generic mfg.
    Review, Journal:  Corticosteroid therapy in IgA Nephropathy: A friend or foe? (Pubmed Central) -  Mar 28, 2023   
    Recent evidence suggests the use of corticosteroids in a selected cohort of people with IgAN at high risk of disease progression can improve kidney outcomes but comes with an associated risk of treatment-related adverse events particularly with higher doses. Management decisions should therefore follow an informed patient-clinician discussion.